Company news

Tianjin Tianyao Pharmaceuticals Co., Ltd. Class A (SSE:600488) news

Tianjin Tianyao Pharmaceuticals Co., Ltd. Class A news releases on 6ix. Latest, Sep 30, 2026: (600488)"TIANJIN TIANYAO PHARMACEUTICAL CO., LTD."Announcement…

Tianjin Tianyao Pharmaceuticals Co., Ltd. Class A (SSE:600488) news

Press releases & updates

(600488)"TIANJIN TIANYAO PHARMACEUTICAL CO., LTD."Announcement on Obtaining Drug Registration Certificate for Nicardipine Hydrochloride Injection by Subsidiary

(600488)"TIANJIN TIANYAO PHARMACEUTICAL CO., LTD."Announcement on Abnormal Fluctuations in Stock Trading

"TIANJIN TIANYAO PHARMACEUTICAL CO., LTD."Announcement on Obtaining Drug Registration Certificate for Ropivacaine Hydrochloride Injection by Subsidiary

"TIANJIN TIANYAO PHARMACEUTICAL CO., LTD."Indicative Announcement on Listing and Transfer of 100% Equity Interest in Shanghai Liuliguang Pharmaceutical Development Co., Ltd. by Shanghai Industrial Investment (Holdings) Co., Ltd. and Shanghai Industrial Investment Development Co., Ltd.

"TIANJIN TIANYAO PHARMACEUTICAL CO., LTD."Announcement on Resolutions of the 1st Meeting of the 10th Board of Directors

"TIANJIN TIANYAO PHARMACEUTICAL CO., LTD."Announcement on Attending the 2026 Online Collective Reception Day for Investors of Listed Companies in Tianjin Jurisdiction

"TIANJIN TIANYAO PHARMACEUTICAL CO., LTD."Announcement on Provision for Impairment and Write-off of Assets for the First Half of 2026

"TIANJIN TIANYAO PHARMACEUTICAL CO., LTD."Announcement on Obtaining the Drug Registration Certificate by the Subsidiary from the Ministry of Health (Myanmar) for Pediatric Compound Amino Acid Injection (18AA-I)

"TIANJIN TIANYAO PHARMACEUTICAL CO., LTD."Announcement on Addition of a New Specification of a Subsidiary's Drug and Passing of the Generic Drug Consistency Evaluation

"TIANJIN TIANYAO PHARMACEUTICAL CO., LTD."Announcement on the Proposed Selection of Subsidiary's Products in the National Centralized Drug Procurement

"TIANJIN TIANYAO PHARMACEUTICAL CO., LTD."Announcement on Obtaining Drug Registration Certificate by Subsidiary

"TIANJIN TIANYAO PHARMACEUTICAL CO., LTD."Announcement on Abnormal Fluctuations in Stock Trading

"TIANJIN TIANYAO PHARMACEUTICAL CO., LTD."Announcement on the Adjustment of the Subsidiary's Pharmaceutical Products in the "National Essential Medicines List"

"TIANJIN TIANYAO PHARMACEUTICAL CO., LTD."Announcement on Implementation of Dividend Distribution for 2025

"TIANJIN TIANYAO PHARMACEUTICAL CO., LTD."Announcement on Obtaining FDA DMF First Adequate Letter for Betamethasone Dipropionate API

"TIANJIN TIANYAO PHARMACEUTICAL CO., LTD."Announcement on Obtaining Drug Registration Certificate for Its Methylprednisolone Tablets from the Ministry of Health of the Republic of Belarus

Announcement on the Subsidiary's Drug Passing Consistency Evaluation of Generic Drug

Announcement on Resolutions of the 27th Meeting of the 9th Board of Directors

Announcement on Convening the 2025 Annual Performance Briefing

Announcement on Obtaining Drug Registration Certificate by Subsidiary

Indicative Announcement on Shanghai Industrial Investment (Holdings) Co., Ltd. and Shanghai Industrial Investment Development Co., Ltd.'s Proposed Public Solicitation of a Transferee for 100% Equity Interest in Shanghai Liuliguang Pharmaceutical Development Co., Ltd.

Announcement on Resolutions of the 2025 Annual General Meeting

Announcement on Abnormal Fluctuations in Stock Trading

Announcement on the 2025 Evaluation Report on ""Corporate Value and Return Enhancement"" and 2026 Action Plan

Announcement on Serious Abnormal Fluctuations in Stock Trading and Risk Warning

Announcement on Receiving Results of GMP Compliance Inspection Concerning Drugs by the Subsidiary

Indicative Announcement on Stock Trading Risk

Announcement on Resolutions of the 25th Meeting of the 9th Board of Directors

Announcement on Changing Signatory Certified Public Accountant

Corrective Action Report on Measures Taken by the Tianjin Office of China Securities Regulatory Commission to Order the Company to Make Corrections and Issue Warning Letters to Relevant Personnel

Announcement on Continuation of Procurement for Products of the Company and Its Subsidiaries that Are Scheduled to Be Selected for National Procurement Continuation After the Expiry of Agreement

Announcement on Receiving Decision on Administrative Supervision Measures from Tianjin Securities Regulatory Bureau

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026

Announcement on Resignation of Senior Management Member

Announcement on Resolutions of the 23rd Meeting of the 9th Board of Directors

Announcement on Resolutions of the 22nd Meeting of the 9th Board of Directors

Announcement on Outline of the Q3 2025 Performance Briefing

津药药业股份有限公司关于子公司注射用甲泼尼龙琥珀酸钠获得巴拿马共和国卫生部注册证书的公告

Announcement on Subsidiary’s Products Being Proposed for Selection in the National Centralized Drug Procurement

Announcement on Convening the Q3 2025 Performance Briefing

Announcement on Attending 2025 Online Collective Reception Day for Investors of Listed Companies in Tianjin Jurisdiction

Announcement on the Company's Receipt of the Notice of Approval for Marketing Application of Chemical APIs

2025 Semi-annual Report

Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025

Announcement on Change of Drug Production License

Announcement on Receiving Results of GMP Compliance Inspection Concerning Drugs

Announcement on Resolutions of the 19th Meeting of the 9th Board of Directors

Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025

Semi-annual Earnings Preannouncement for 2025

Announcement on Subsidiary's Drug Passing Generic Drug Consistency Evaluation